Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones

  • J Med Chem. 2003 Jan 30;46(3):349-52. doi: 10.1021/jm025585h.
Steven L Colletti  1 ,  Jessica L Frie ,  Elizabeth C Dixon ,  Suresh B Singh ,  Bernard K Choi ,  Giovanna Scapin ,  Catherine E Fitzgerald ,  Sanjeev Kumar ,  Elizabeth A Nichols ,  Stephen J O'Keefe ,  Edward A O'Neill ,  Gene Porter ,  Koppara Samuel ,  Dennis M Schmatz ,  Cheryl D Schwartz ,  Wesley L Shoop ,  Chris M Thompson ,  James E Thompson ,  Ruixiu Wang ,  Andrea Woods ,  Dennis M Zaller ,  James B Doherty
Affiliations
  • 1. Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065, USA. [email protected]
PMID: 12540232 DOI: 10.1021/jm025585h
Abstract

Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors.